EZZ Life Science Holdings Ltd. (AU:EZZ) has released an update.
EZZ Life Science Holdings Ltd. reported substantial growth with customer receipts rising to $23.0m, a 70.3% increase from the previous year, and operating cash flows surged by 120.3% to $4.5 million in Q4 FY24. The company maintained a strong debt-free cash position of $19.0m and continued to reward shareholders by paying a fully franked interim dividend. Additionally, EZZ is expanding globally with new product launches, a significant sales agreement with Pinehills (Hong Kong) Ltd., and securing FDA approval for entry into the US market.
For further insights into AU:EZZ stock, check out TipRanks’ Stock Analysis page.
